CURIS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CURIS, INC. (CRIS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-02-24
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $140.00K.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was -$231.00K.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $7.17M.
- CURIS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-03 | |||
| 2020-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$91.00K derived: sum of 2 quarters · filed 2022-02-24 | $7.17M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$231.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.03M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $7.26M 10-Q · filed 2021-08-03 | |||
| 2019-12-31 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.05M derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.05M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $1.05M 10-Q · filed 2020-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |